Phase 2 Melanoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 18 years or older
- People who have been diagnosed with primary skin melanoma (confirmed by laboratory testing of tissue) where the tumour measures more than 2.0 mm in depth
- People who are already scheduled to have surgery to remove more tissue around the original tumour site and to have a sentinel node biopsy (a procedure to check nearby lymph nodes for cancer spread)
- People who are generally well enough to carry out normal daily activities with little or no limitation, as measured by a standard health scale (WHO Performance Status of 0 or 1)
- People who agree to use reliable contraception from the start of the study until at least 90 days after receiving the study drug (IMO-2125)
- People who are willing and able to provide written informed consent
Who may not be able to join:
- People with a known allergy or sensitivity to a type of molecule called oligodeoxynucleotides (confirm with trial site)
- People who currently have an active autoimmune disease that requires ongoing treatment to manage it
- People whose cancer has been confirmed by testing to have spread to nearby areas or to other parts of the body
- People whose melanoma did not originate in the skin (for example, eye or internal melanoma)
- People who have or have had another separate primary cancer, although some exceptions may apply (confirm with trial site)
- People who currently have an active infection in their body that requires antibiotic treatment
- People who are pregnant or currently breastfeeding
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Tanja de Gruijl, Amsterdam UMC, location VUmc
Phone: +3120 4444881
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
The rate of tumor positive sentinal lymph node (SLN)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 7 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.